Computational Study Flags Benzimidazole Compounds That May Fight Inflammation and Allergy at Once

Millions of people who suffer from allergic rhinitis, chronic urticaria, or atopic dermatitis know the routine well: one pill for the allergy, another for the inflammation that so often travels with it. A new computational study published in the journal Discover Chemistry suggests that this two-drug burden might one day be reduced to a single molecule. Researchers Sandesh Pawar and Prathamesh Panzade of Pravara Rural College of Pharmacy in Maharashtra, India, designed eleven novel benzimidazole derivatives and ran them through a complete in silico pipeline, screening them simultaneously against cyclooxygenase-2, the enzyme central to inflammation, and the histamine H1 receptor, the classic target of antihistamines. Three of their virtual compounds outperformed established drugs on one or both targets, and the authors argue they now deserve to be synthesized and tested in the laboratory.

The therapeutic logic behind the work rests on the deep biological overlap between inflammatory and allergic disease. COX-2 catalyzes the conversion of arachidonic acid into prostaglandins when tissues become inflamed, driving pain, fever, and swelling, while histamine acting through H1 receptors triggers vasodilation, smooth muscle contraction, and itching. In conditions such as allergic rhinitis with sinus inflammation or chronic urticaria with an inflammatory component, both pathways fire at once. A compound that engages both could, in principle, deliver synergistic benefit, lower the effective dose of each mechanism, reduce drug-drug interactions, and improve patient adherence. The authors point to rupatadine, which combines H1 antagonism with platelet-activating factor inhibition, as an existing proof that multi-target antihistamines can succeed clinically.

The benzimidazole scaffold was a deliberate choice. This fused benzene-imidazole ring system structurally resembles the purine bases of DNA, which helps it form favorable contacts with a wide range of biological targets. Benzimidazole drugs already span an impressive pharmacological range, from anti-inflammatory and antimicrobial to antiviral, anticancer, and antiparasitic activity. Previous studies have shown that suitably substituted benzimidazoles can act as selective COX-2 inhibitors with improved gastrointestinal safety compared with traditional NSAIDs; one reported series of methyl sulfonyl-substituted analogues achieved sub-micromolar inhibitory potency in enzyme assays. What had not been done before, according to the authors, was a systematic dual-target evaluation of a single benzimidazole series against both COX-2 and the H1 receptor.

The design itself was methodical. All eleven compounds, labeled SP1 through SP11, share a 2-phenyl-1H-benzimidazole core connected through an acetamide linker at the N-1 position to a variable substituent. That substituent was varied deliberately across chemical space: aromatic groups such as aniline and resorcinol, aldehyde-bearing moieties including salicylaldehyde and isovanillin, carboxylic acids ranging from formic to benzoic, chloroacetic, and salicylic acid, and simple aliphatic propanol and butanol chains. Each variation tunes lipophilicity, hydrogen-bonding capacity, and steric profile in a different way, allowing the team to read out structure-activity relationships directly from the docking results.

Before any docking was attempted, the compounds had to pass basic drug-likeness filters. Using the SwissADME web platform, the researchers confirmed that every derivative satisfied Lipinski’s Rule of Five and Veber’s oral bioavailability criteria without a single violation. Molecular weights ranged from 279.29 to 385.42 daltons, comfortably below the 500-dalton ceiling, while calculated LogP values between 1.02 and 3.72 suggested a workable balance between membrane permeability and aqueous solubility. Topological polar surface area values of 46.92 to 84.22 square angstroms and rotatable bond counts of five to seven fell within Veber’s limits, predicting efficient passive diffusion across the gut wall. In short, all eleven molecules looked like plausible oral drugs on paper.

Safety screening came next, using ProTox-III, a machine-learning platform trained on curated toxicological datasets. Predicted acute oral LD50 values ranged from 500 to 2000 milligrams per kilogram, placing every compound in GHS Toxicity Class IV, a category comparable to many approved pharmaceuticals. Human intestinal absorption was predicted to exceed 80 percent for the entire series, and carcinogenicity and mutagenicity predictions were negative for nearly all derivatives. Notably, low predicted blood-brain barrier penetration for most compounds hints at a peripherally acting antihistamine with reduced sedation risk, the defining drawback of first-generation H1 antagonists. One caution did emerge: SP7 and SP8 showed moderate predicted cardiotoxicity, a signal the authors stress must be verified with hERG channel assays, since cardiac liability contributed to the market withdrawal of some earlier COX-2 inhibitors.

The docking results were where the study delivered its headline findings. Using Schrödinger’s Glide Extra Precision protocol against human COX-2, the crystal structure of which was solved bound to ibuprofen, the team found that SP2, a resorcinol derivative, scored minus 8.032 kilocalories per mole and SP8, a salicylic acid derivative, scored minus 9.566 kilocalories per mole, both far ahead of ibuprofen’s benchmark of minus 5.779. The protocol was validated by re-docking the co-crystallized ligands, yielding root-mean-square deviations of 1.83 and 1.78 angstroms for COX-2 and the H1 receptor respectively, both under the accepted 2.0-angstrom threshold. SP8’s strength appears to come from its ortho-hydroxyl and carboxylate groups working in concert: the carboxylate forms a salt bridge with Arg120 while hydrogen bonds anchor to Tyr355 and Ser530, and hydrophobic packing into the enzyme’s channel stabilizes the complex.

Against the histamine H1 receptor, solved by cryo-electron microscopy in complex with desloratadine, the top performers were SP2 at minus 8.021 and SP11, a butanol-bearing derivative, at minus 8.627 kilocalories per mole, both surpassing the reference antihistamine astemizole at minus 6.519. These compounds engage the orthosteric binding pocket through hydrogen bonds with Asp107, Tyr108, Ser111, and Asn198, complemented by aromatic stacking against Trp428, Tyr431, and Phe432. The extended butyl chain of SP11 appears to fill hydrophobic sub-pockets lined by Phe432, Phe435, and Trp428, consistent with established structure-activity rules for lipophilic H1 ligands. Intriguingly, the SAR analysis suggested that lengthening the alkyl chain preferentially boosts H1 affinity over COX-2 affinity, giving medicinal chemists a tunable dial for target balance.

When docking affinity, drug-likeness, and predicted safety were weighed together, three compounds rose to the top for different reasons. SP2 shows the most balanced dual-target engagement, with its COX-2 and H1 docking scores within 0.1 kilocalories per mole of each other. SP8 is the strongest single COX-2 binder of the series, and SP11 the strongest H1 binder. A fourth compound, SP9, showed promising H1-selective trends thanks to a methoxy group that occupies a hydrophobic sub-pocket absent from COX-2, but its overall dual-target and safety profile did not outperform the three leads, so it was not carried forward. The authors are careful to note that GlideScores are empirical rankings, not thermodynamic binding free energies, and cannot substitute for measured inhibition constants.

That caveat frames the study’s honest limitations. Static docking cannot capture protein flexibility or induced-fit effects, and machine-learning ADMET models can be unreliable for chemotypes poorly represented in their training data. The authors recommend a clear experimental roadmap: synthesize SP2, SP8, and SP11; run in vitro COX-2 inhibition and H1 receptor binding assays; establish COX-1/COX-2 selectivity to gauge gastrointestinal risk; complete full experimental ADMET profiling including hERG testing; and then move to in vivo efficacy studies in inflammation and anaphylaxis models, with molecular dynamics simulations guiding further optimization. Until those experiments are done, the dual-acting promise of these molecules remains a well-supported hypothesis rather than a demonstrated therapy. Still, as a rational, hypothesis-generating screen, the work offers a concrete starting point for a next generation of medicines aimed at the frequent clinical overlap between allergy and inflammation.

Subject of Research: Computational evaluation of novel benzimidazole derivatives as dual COX-2 inhibitors and histamine H1 receptor antagonists

Article Title: Integrated computational evaluation of novel benzimidazole scaffolds as dual COX-2 inhibitory and histamine H1 antagonistic activity

Article References: Pawar, S., & Panzade, P. (2026). Integrated computational evaluation of novel benzimidazole scaffolds as dual COX-2 inhibitory and histamine H1 antagonistic activity. Discover Chemistry, 3(1), Article 566. https://doi.org/10.1007/s44371-026-01024-6

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01024-6

Keywords: benzimidazole, COX-2 inhibition, histamine H1 receptor, molecular docking, drug-likeness, ADMET prediction, SwissADME, ProTox-III, Glide XP docking, structure-activity relationship, computer-aided drug design, dual-target therapeutics